This figure compares to our segmental projection of $557 million.Per management, Bioprocessing (representing about two-thirds of the segment) delivered low single-digit growth in the first quarter of 2025. This performance was supported by solid demand for process ingredients and excipients, as well as double-digit growth in single-use offerings like Masterflex. However, these gains were partially offset by softer demand for controlled environment consumables—critical for maintaining clean room integrity—as customers optimized usage in response to macroeconomic pressures. Despite this near-term weakness, the segment's order book remained robust, reflecting sustained momentum in bioprocessing and reinforcing confidence in a gradual recovery moving forward.AVTR's Margin AnalysisIn the quarter under review, Avantor's gross profit declined 6.2% year over year to $534.9 million. The gross margin contracted 14 basis points (bps) to 33.8%.